153 related articles for article (PubMed ID: 35041419)
1. Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of
Smith CR; Aranda R; Bobinski TP; Briere DM; Burns AC; Christensen JG; Clarine J; Engstrom LD; Gunn RJ; Ivetac A; Jean-Baptiste R; Ketcham JM; Kobayashi M; Kuehler J; Kulyk S; Lawson JD; Moya K; Olson P; Rahbaek L; Thomas NC; Wang X; Waters LM; Marx MA
J Med Chem; 2022 Feb; 65(3):1749-1766. PubMed ID: 35041419
[TBL] [Abstract][Full Text] [Related]
2. Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5.
Mavrakis KJ; McDonald ER; Schlabach MR; Billy E; Hoffman GR; deWeck A; Ruddy DA; Venkatesan K; Yu J; McAllister G; Stump M; deBeaumont R; Ho S; Yue Y; Liu Y; Yan-Neale Y; Yang G; Lin F; Yin H; Gao H; Kipp DR; Zhao S; McNamara JT; Sprague ER; Zheng B; Lin Y; Cho YS; Gu J; Crawford K; Ciccone D; Vitari AC; Lai A; Capka V; Hurov K; Porter JA; Tallarico J; Mickanin C; Lees E; Pagliarini R; Keen N; Schmelzle T; Hofmann F; Stegmeier F; Sellers WR
Science; 2016 Mar; 351(6278):1208-13. PubMed ID: 26912361
[TBL] [Abstract][Full Text] [Related]
3. MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer.
Engstrom LD; Aranda R; Waters L; Moya K; Bowcut V; Vegar L; Trinh D; Hebbert A; Smith CR; Kulyk S; Lawson JD; He L; Hover LD; Fernandez-Banet J; Hallin J; Vanderpool D; Briere DM; Blaj A; Marx MA; Rodon J; Offin M; Arbour KC; Johnson ML; Kwiatkowski DJ; Jänne PA; Haddox CL; Papadopoulos KP; Henry JT; Leventakos K; Christensen JG; Shazer R; Olson P
Cancer Discov; 2023 Nov; 13(11):2412-2431. PubMed ID: 37552839
[TBL] [Abstract][Full Text] [Related]
4. Homozygous MTAP deletion in primary human glioblastoma is not associated with elevation of methylthioadenosine.
Barekatain Y; Ackroyd JJ; Yan VC; Khadka S; Wang L; Chen KC; Poral AH; Tran T; Georgiou DK; Arthur K; Lin YH; Satani N; Ballato ES; Behr EI; deCarvalho AC; Verhaak RGW; de Groot J; Huse JT; Asara JM; Kalluri R; Muller FL
Nat Commun; 2021 Jul; 12(1):4228. PubMed ID: 34244484
[TBL] [Abstract][Full Text] [Related]
5. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells.
Kryukov GV; Wilson FH; Ruth JR; Paulk J; Tsherniak A; Marlow SE; Vazquez F; Weir BA; Fitzgerald ME; Tanaka M; Bielski CM; Scott JM; Dennis C; Cowley GS; Boehm JS; Root DE; Golub TR; Clish CB; Bradner JE; Hahn WC; Garraway LA
Science; 2016 Mar; 351(6278):1214-8. PubMed ID: 26912360
[TBL] [Abstract][Full Text] [Related]
6. Design and evaluation of achiral, non-atropisomeric 4-(aminomethyl)phthalazin-1(2H)-one derivatives as novel PRMT5/MTA inhibitors.
Smith CR; Aranda R; Christensen JG; Engstrom LD; Gunn RJ; Ivetac A; Ketcham JM; Kuehler J; David Lawson J; Marx MA; Olson P; Thomas NC; Wang X; Waters LM; Kulyk S
Bioorg Med Chem; 2022 Oct; 71():116947. PubMed ID: 35926325
[TBL] [Abstract][Full Text] [Related]
7. MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis.
Marjon K; Cameron MJ; Quang P; Clasquin MF; Mandley E; Kunii K; McVay M; Choe S; Kernytsky A; Gross S; Konteatis Z; Murtie J; Blake ML; Travins J; Dorsch M; Biller SA; Marks KM
Cell Rep; 2016 Apr; 15(3):574-587. PubMed ID: 27068473
[TBL] [Abstract][Full Text] [Related]
8. Selective PRMT5 Inhibitors Suppress Human CD8
Strobl CD; Schaffer S; Haug T; Völkl S; Peter K; Singer K; Böttcher M; Mougiakakos D; Mackensen A; Aigner M
Mol Cancer Ther; 2020 Feb; 19(2):409-419. PubMed ID: 31712395
[TBL] [Abstract][Full Text] [Related]
9. PRMT5 silencing selectively affects MTAP-deleted mesothelioma: In vitro evidence of a novel promising approach.
Barbarino M; Cesari D; Bottaro M; Luzzi L; Namagerdi A; Bertolino FM; Bellan C; Proietti F; Somma P; Micheli M; de Santi MM; Guazzo R; Mutti L; Pirtoli L; Paladini P; Indovina P; Giordano A
J Cell Mol Med; 2020 May; 24(10):5565-5577. PubMed ID: 32301278
[TBL] [Abstract][Full Text] [Related]
10. Combined inhibition of MTAP and MAT2a mimics synthetic lethality in tumor models via PRMT5 inhibition.
Bedard GT; Gilaj N; Peregrina K; Brew I; Tosti E; Shaffer K; Tyler PC; Edelmann W; Augenlicht LH; Schramm VL
J Biol Chem; 2024 Jan; 300(1):105492. PubMed ID: 38000655
[TBL] [Abstract][Full Text] [Related]
11. Extracellular 5'-methylthioadenosine inhibits intracellular symmetric dimethylarginine protein methylation of FUSE-binding proteins.
Tang B; Lee HO; Gupta S; Wang L; Kurimchak AM; Duncan JS; Kruger WD
J Biol Chem; 2022 Sep; 298(9):102367. PubMed ID: 35963436
[TBL] [Abstract][Full Text] [Related]
12. Early Clinical Success of MTA-Cooperative PRMT5 Inhibitors for the Treatment of CDKN2A/MTAP-Deleted Cancers.
Mulvaney KM
Cancer Discov; 2023 Nov; 13(11):2310-2312. PubMed ID: 37909092
[TBL] [Abstract][Full Text] [Related]
13. MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA Damage.
Kalev P; Hyer ML; Gross S; Konteatis Z; Chen CC; Fletcher M; Lein M; Aguado-Fraile E; Frank V; Barnett A; Mandley E; Goldford J; Chen Y; Sellers K; Hayes S; Lizotte K; Quang P; Tuncay Y; Clasquin M; Peters R; Weier J; Simone E; Murtie J; Liu W; Nagaraja R; Dang L; Sui Z; Biller SA; Travins J; Marks KM; Marjon K
Cancer Cell; 2021 Feb; 39(2):209-224.e11. PubMed ID: 33450196
[TBL] [Abstract][Full Text] [Related]
14. Transition state analogue of MTAP extends lifespan of APC
Firestone RS; Feng M; Basu I; Peregrina K; Augenlicht LH; Schramm VL
Sci Rep; 2021 Apr; 11(1):8844. PubMed ID: 33893330
[TBL] [Abstract][Full Text] [Related]
15. Fragment optimization and elaboration strategies - the discovery of two lead series of PRMT5/MTA inhibitors from five fragment hits.
Smith CR; Kulyk S; Ahmad MUD; Arkhipova V; Christensen JG; Gunn RJ; Ivetac A; Ketcham JM; Kuehler J; Lawson JD; Thomas NC; Wang X; Marx MA
RSC Med Chem; 2022 Dec; 13(12):1549-1564. PubMed ID: 36545438
[TBL] [Abstract][Full Text] [Related]
16. Specific Targeting of
Tang B; Lee HO; An SS; Cai KQ; Kruger WD
Cancer Res; 2018 Aug; 78(15):4386-4395. PubMed ID: 29844120
[TBL] [Abstract][Full Text] [Related]
17. Growth and metastases of human lung cancer are inhibited in mouse xenografts by a transition state analogue of 5'-methylthioadenosine phosphorylase.
Basu I; Locker J; Cassera MB; Belbin TJ; Merino EF; Dong X; Hemeon I; Evans GB; Guha C; Schramm VL
J Biol Chem; 2011 Feb; 286(6):4902-11. PubMed ID: 21135097
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss.
Fedoriw A; Rajapurkar SR; O'Brien S; Gerhart SV; Mitchell LH; Adams ND; Rioux N; Lingaraj T; Ribich SA; Pappalardi MB; Shah N; Laraio J; Liu Y; Butticello M; Carpenter CL; Creasy C; Korenchuk S; McCabe MT; McHugh CF; Nagarajan R; Wagner C; Zappacosta F; Annan R; Concha NO; Thomas RA; Hart TK; Smith JJ; Copeland RA; Moyer MP; Campbell J; Stickland K; Mills J; Jacques-O'Hagan S; Allain C; Johnston D; Raimondi A; Porter Scott M; Waters N; Swinger K; Boriack-Sjodin A; Riera T; Shapiro G; Chesworth R; Prinjha RK; Kruger RG; Barbash O; Mohammad HP
Cancer Cell; 2019 Jul; 36(1):100-114.e25. PubMed ID: 31257072
[TBL] [Abstract][Full Text] [Related]
19. Transcriptional perturbation of protein arginine methyltransferase-5 exhibits MTAP-selective oncosuppression.
Busacca S; Zhang Q; Sharkey A; Dawson AG; Moore DA; Waller DA; Nakas A; Jones C; Cain K; Luo JL; Salcedo A; Salaroglio IC; Riganti C; Le Quesne J; John T; Boutros PC; Zhang SD; Fennell DA
Sci Rep; 2021 Apr; 11(1):7434. PubMed ID: 33795785
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of methylthioadenosine phosphorylase (MTAP) induces progression of hepatocellular carcinoma via accumulation of 5'-deoxy-5'-methylthioadenosine (MTA).
Kirovski G; Stevens AP; Czech B; Dettmer K; Weiss TS; Wild P; Hartmann A; Bosserhoff AK; Oefner PJ; Hellerbrand C
Am J Pathol; 2011 Mar; 178(3):1145-52. PubMed ID: 21356366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
